ArticleMolecular therapy. Advances2026
Neurodevelopmental miR-135a-1-3p and miR-135b-3p promote long-distance axon regeneration after injury in the central visual pathway.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Micro-RNAs (miRNAs) play roles in the mammalian central nervous system (CNS) development and disease but the functions of specific miRNA families' members in defined neuronal types are poorly understood. Here, we characterized the miR-135 family members in the mouse CNS retinal ganglion cell (RGC) and cortical projection neurons development, and tested whether reverting expression toward embryonic levels for the identified developmentally regulated miR-135 family members may reactivate the intrinsic axon growth capacity following axonal injury in the adult CNS. We found that two-out-of-five miR-135 family members, miR-135a-1-3p and miR-135b-3p, were developmentally downregulated, with further downregulation after axonal injury, in neurons. Importantly, RGC-targeted mimics of miR-135a-1-3p and miR-135b-3p promoted neuroprotection and axon regeneration following optic nerve injury, with axons regrowing through a segment of the central visual pathway when co-treated with an axon growth-supporting small fibronectin-based recombinant protein. Finally, transcriptomic profiling of the treated RGCs showed that genes involved in neurodevelopment/neuroprotection were embedded in the gene networks affected by the treatments. Thus, miR-135a-1-3p and miR-135b-3p are developmentally downregulated in the mammalian CNS projection neurons and present options for translation toward CNS injury treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.